8
Registered trials
4
Recruiting
7
Unique sponsors
21
Unique IMPs
6
Commercial trials
Drug classes (ATC)
—
ATC code not specified
4
H
Endocrinology (ATC H)
1
L
Oncology (ATC L)
4
N
Neurology/Psychiatry (ATC N)
4
R
Respiratory (ATC R)
1
V
Various (ATC V)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
5 substances
BTK inhibitor
3 substances
Antimetabolite
2 substances
Corticosteroid
2 substances
Monoclonal antibody (tumor, humanized)
2 substances
CAR-T cell therapy
1 substance
Alkylating agent
1 substance
Analgesic / antipyretic
1 substance
Monoclonal antibody (immune, humanized)
1 substance
Monoclonal antibody
1 substance
IMiD
1 substance
Monoclonal antibody (chimeric)
1 substance
Phase III:
1
Phase II:
3
Phase I/II:
2
Phase I:
2
Phase III
1 trial-
RecruitingF. Hoffmann-La Roche AG CommercialBENDAMUSTINE HYDROCHLORIDE; GLOFITAMAB; LENALIDOMIDE; OBINUTUZUMAB; RITUXIMAB; TOCILIZUMAB
Phase II
3 trials-
EndedKite Pharma Inc. CommercialACALABRUTINIB; BREXUCABTAGENE AUTOLEUCEL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIPHENHYDRAMINE HYDROCHLORIDE; FLUDARABINE PHOSPHATE; IBRUTINIB; MESNA; METHYLPREDNISOLONE; PARACETAMOL; TOCILIZUMAB
-
ExpiredFondazione IRCCS Istituto Nazionale Dei Tumori AcademicBREXUCABTAGENE AUTOLEUCEL; IBRUTINIB
-
EndedFondazione Italiana Linfomi Ets AcademicIMP not specified
Phase I/II
2 trials-
EndedBeOne Medicines AG CommercialN-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SULFONYL]-4-(2-{(2S)-2-[2-(PROPAN-2-YL)PHENYL]PYRROLIDIN1-YL}-7-AZASPIRO[3.5]NONAN-7-YL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5- YL)OXY]BENZAMIDE
-
RecruitingBeOne Medicines AG CommercialBGB-16673; GLOFITAMAB; MOSUNETUZUMAB; N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SULFONYL]-4-(2-{(2S)-2-[2-(PROPAN-2-YL)PHENYL]PYRROLIDIN1-YL}-7-AZASPIRO[3.5]NONAN-7-YL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5- YL)OXY]BENZAMIDE; OBINUTUZUMAB; ZANUBRUTINIB
Phase I
2 trials-
RecruitingExscientia AI Limited CommercialIMP not specified
-
RecruitingFamicordtx S.A. CommercialIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| BeOne Medicines AG | Commercial | 2 | Phase I/II | 1 |
| Exscientia AI Limited | Commercial | 1 | Phase I | 1 |
| Famicordtx S.A. | Commercial | 1 | Phase I | 1 |
| Kite Pharma Inc. | Commercial | 1 | Phase II | 0 |
| F. Hoffmann-La Roche AG | Commercial | 1 | Phase III | 1 |
| Fondazione IRCCS Istituto Nazionale Dei Tumori | Academic | 1 | Phase II | 0 |
| Fondazione Italiana Linfomi Ets | Academic | 1 | Phase II | 0 |
New trials by year
2022
1
2023
3
2025
3